Fertitta Edges Icahn: Exclusive Talks to Buy Caesars for $7B
Billionaire Tilman Fertitta leads exclusive talks to acquire Caesars Entertainment at ~$34/share, topping Carl Icahn's rival bid in a potential $7B casino deal.
NOTRELOAD AI
Solid Biosciences Reports Strong Interim Results for SGT-003 Gene Therapy in Duchenne Trial
Solid Biosciences’ gene therapy SGT-003 shows early promise for Duchenne; trial patients improved muscle and heart function, with potential accelerated FDA approval in 2026.
Papa John's Gets Fresh Takeover Offer: Qatari-Backed Irth Eyes $47/Share Deal
A Qatari-backed investment fund, Irth Capital Management, has bid $47 per share to buy Papa John's pizza chain, valuing it at ~$1.5 billion—a big premium over its recent stock price amid ongoing takeover interest.
Pokémon Pokopia: The Cozy Hit That's Selling Out and Skyrocketing Nintendo Shares
Pokémon Pokopia, a cozy Animal Crossing-style life sim for Switch 2, is selling out at retailers and sending Nintendo shares up 6% in the U.S.
Tesla China Roars Back: 58,599 Vehicles Sold in February, Fourth Straight Month of Gains
Tesla China's February 2026 wholesale sales hit 58,599 vehicles, up 91% year-over-year from a low base in 2025. Despite a monthly dip, exports surged and financing deals help boost demand in a competitive market.
Wells Fargo gives Atrium Therapeutics a Strong Buy rating on its rare cardiomyopathy programs
Wells Fargo analyst initiates coverage on Atrium Therapeutics with Overweight rating and $25 price target, highlighting big potential in RNA therapies for rare genetic heart diseases with no current treatments.